Crescent Biopharma announced its second quarter 2026 financial results, highlighting progress in clinical trials for its cancer therapies, including CR-001, a PD-1 x VEGF bispecific antibody, and ADC candidates CR-002 and CR-003. The company is enrolling patients globally in multiple trials, with key data expected starting Q1 2027. Crescent also completed a $143.7 million public offering, extending its cash runway into the second half of 2028, supporting ongoing development and upcoming clinical milestones.
Ferrari reported Q2 2026 net revenues of €1.94 billion, up 8% year-on-year, driven by a richer product mix and increased personalization sales. Operating profit rose 10% to €605 million with a margin of 31.2%, while net profit grew 9% to €463 million...
Dimensional Fund Advisors Ltd. has publicly disclosed holding a 1.58% stake in Gamma Communications PLC as of July 29, 2026. The disclosure, made under Rule 8.3 of the Takeover Code, indicates ownership of 1,414,785 ordinary shares. This filing is a ...
Microsoft's Q2 results reveal robust fundamentals, including 18% year-over-year revenue growth and strong 26% unlevered free cash flow margins despite increased capital expenditures. The company's rapidly expanding order backlog, up 84% year-over-yea...
Cycurion secured its largest contract ever, a $54.6 million, 10-year deal with a top-5 global consulting firm to modernize and secure a state government's Health and Human Services System. The contract will generate over $5 million annually starting ...
Core AI Holdings has formed Z Studio, a new business unit dedicated to creating and scaling AI-powered consumer applications across various vertical markets. This initiative aims to expand Core AI's strategy beyond individual products by establishing...
